Measurement of Free Versus Total Therapeutic Monoclonal Antibody in Pharmacokinetic Assessment is Modulated by Affinity, Incubation Time, and Bioanalytical PlatformTalbot JJ, et al., AAPS J, 17(6):1446-54, 2015
Physicochemical and Biological Characterization of a Biosimilar TrastuzumabLopez-Morales C, et al., Biomed Res Int, 2015:427235, 2015
Practical Quantitative and Kinetic Applications of Bio-Layer Interferometry for Toxicokinetic Analysis of a Monoclonal Antibody TherapeuticDysinger, M.; King, L.E., J Immunological Methods, 379(1-2), 30-41, 2012
Challenges in Developing Bioanalytical Assays for Characterization of Antibody-Drug ConjugatesStephan, J.P. ; Kozak, K R.; Wong, W.L., Bioanalysis, 3(6), 677-700, 2011
Detection of Low-Affinity Anti-Drug Antibodies and Improved Drug Tolerance in Immunogenicity Testing by Octet Biolayer InterferometryLi, J., et al., J Pharm Biomed Anal, 54(2), 286-294, 2010
Octet - An Efficient Tool for Ligand Binding Assays (LBA)
Judy Shih, Ph.D., Pharmacokinetics and Drug Metabolism, Amgen, Octet System User Workshop - NBC, 2012 Quality assay reagent is the key for ligand binding assays, particularly for assay specificity and sensitivity. Assay reagent screening, characterization and selection process has been well established. ELISA has been widely and routinely used. Complementary tools include Biocore and cell based assays. This presentation demonstrates that the Octet platform is another complementary tool with high throughput and increased efficiency. Two case studies address assay reagent screening, paring, and bridging assessment. The third case study describes how the Octet platform facilitated assay troubleshooting. Furthermore, the platform has been implemented for reagent biotinylation assessment. In summary, the Octet platform is an efficient tool for ligand binding assays.
© 2020 Molecular Devices. All Rights Reserved.